Cash Flow Statement (Annual)
LJPC / La Jolla Pharmaceutical Co. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
|Net Cash Provided By Used In Operating Activities|
|Net Income Loss||-3,760||-11,548||-7,737||-17,935||-21,313||-41,912||-78,185||-114,803|
|Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities|
|Share Based Compensation||489||254||8,604||12,373||8,992||11,551||14,349||20,776|
|Gain Loss On Disposition Of Assets1||-||-||-||0||0||-16||-75||-199|
|Interest Expense Borrowings||-||-||-||-||-||-||-||-|
|Increase Decrease In Operating Capital|
|Increase Decrease In Accounts Receivable||-||-||-||-||-||-||-||-|
|Increase Decrease In Inventories And Other Operating Assets||-||-||-||-||-||-||-||-|
|Increase Decrease In Prepaid Deferred Expense And Other Assets||-519||-7||-35||18||94||-824||664||1,642|
|Increase Decrease In Other Operating Assets||-||-||-||0||0||70||149||-219|
|Increase Decrease In Accounts Payable And Accrued Liabilities||-231||31||-49||822||-104||2,322||3,600||4,832|
|Increase Decrease In Accrued Liabilities And Other Operating Liabilities||-||-||-||80||739||-248||227||-202|
|Increase Decrease In Employee Related Liabilities||-88||-78||10||56||324||666||987||2,918|
|Increase Decrease In Deferred Rent||-||-||-||-||-||0||124||335|
|Net Cash Provided By Used In Operating Activities||-3,391||-1,826||-2,135||-4,734||-12,879||-25,183||-58,672||-84,881|
|Net Cash Provided By Used In Investing Activities|
|Payments To Acquire Property Plant And Equipment||-||-||0||43||258||1,816||2,218||9,194|
|Net Cash Provided By Used In Investing Activities||-||-||0||-43||-258||-1,816||-2,218||-9,194|
|Net Cash Provided By Used In Financing Activities|
|Proceeds From Royalties Financing||-||-||-||-||-||-||-||-|
|Proceeds From Issuance Of Common Stock||-||-||0||6,751||53,063||104,596||0||117,480|
|Proceeds From Stock Options Exercised||-||0||0||0||0||315||149||2,693|
|Net Cash Provided By Used In Financing Activities||6,003||-||500||10,001||53,063||104,911||149||119,264|
|Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect||-||-||-||-||-||-||-||-|
|Cash Cash Equivalents And Short Term Investments|
|Cash And Cash Equivalents At Carrying Value||-||5,040||3,405||8,629||48,555||126,467||65,726||90,915|
|Restricted Cash Current||-||-||-||-||-||-||-||-|
|Restricted Cash Noncurrent||-||-||-||-||-||-||-||-|
|Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents||-||-||-||-||-||-||-||-|
Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)
APEN / Apollo Endosurgery Inc.
ARIA / ARIAD Pharmaceuticals, Inc.
AVIR / Aviragen Therapeutics, Inc.
AVXS / AveXis, Inc.
BOTA / Biota Pharmaceuticals, Inc.
CASI / CASI Pharmaceuticals, Inc.
CYTR / CytRx Corp.
EIGR / Eiger BioPharmaceuticals, Inc.
FENC / Fennec Pharmaceuticals Inc.
Related News Stories
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (298-9)
Biotechnology stocks have a reputation for being some of the most speculative, most volatile stocks out there. Investors and would-be investors have to stay alert to avoid getting burned. One encouraging sign in any company is when insiders put their money where their mouth is and buy shares. Lately, some insiders at biotech companies have been doing just that, sometimes taking advantage of share price moves (not to mention buy windows opening up) in the wake of the release of quarterly reports. (24-12)
La Jolla Pharmaceutical Co (NASDAQ:LJPC) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET (0-1)
Galectin Therapeutics (NASDAQ:GALT) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (NYSEARCA:IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise of a key departing officer continued to weigh on the price. Based on the recent Form 4 Filings, the selling pressure has abated because the officers have simply run out of options to sell. (24-2)
Biotech stocks represent a peculiar conundrum. On one hand, they are scientifically the most exciting investment sector. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. But the industry is heavily marked with failures and agonizing disappointments. (7-1)
as of ET